About Synthon MENU Synthon global About SynthonStrategySites & officesHistorySocial ResponsibilityPress releasesContact History Synthon was founded in 1991. Within two years, our creative vision and passion for making healthcare more affordable led to the development of a generic version of dobutamine, a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. The success of this first product marked the start of our rapid international growth. Synthon quickly grew from a Nijmegen-based company employing fewer than a hundred people into the fully-fledged company it is today with laboratories, offices and production plants in nine countries around the world and products currently approved by regulatory agencies in around 100 countries worldwide. Our milestones 1991-2001 1991: Founded in the Netherlands 1993: Launched first product: generic dobutamine 1994: Opened R&D facility in the Czech Republic 1997: Opened office in the U.S. 1998: Acquired drug product manufacturing facility in Spain 2000: Acquired API production facility in the Czech Republic 2001: Acquired API production facility in Argentina 2001-2011 2003: Introduced simvastatin 2006: Introduced tamsulosin 2007: Acquired Laboratorios Rider in Chile 2009: Opened new R&D and production unit in the Czech Republic 2009: Opened office in Russia 2010: Acquired Laboratorios Nafar in Mexico 2010: Opened office in South Korea 2011-now 2012: Multi-purpose GMP drug manufacturing facility in Chile operational 2012: Inauguration of R&D pilot plant in Argentina 2014: Opened new API plant in Argentina 2015: Successful completion of Phase III clinical trial with glatiramer acetate 20 mg/ml 2016: Approval obtained for glatiramer acetate 20 mg/mL in Europe 2016: Opened laboratory dedicated to the development of high-potent molecules in Chile 2017: Approval obtained for glatiramer acetate 40 mg/ml in Europe 2019: BC Partners acquires Synthon International Holding B.V. Share this page About Synthon Strategy Sites & offices History Social Responsibility Press releases Our business Research & Development Product portfolio Business development Report Adverse Event Careers Job openings Open applications Terms of Use Privacy and Cookie Statement Made by Zuiderlicht